Inventiva 향후 성장
Future 기준 점검 3/6
Inventiva (는) 각각 연간 53% 및 51.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 40.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 33.8% 로 예상됩니다.
핵심 정보
53.0%
이익 성장률
40.08%
EPS 성장률
| Biotechs 이익 성장 | 58.5% |
| 매출 성장률 | 51.3% |
| 향후 자기자본이익률 | 33.81% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 12 Jun 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • Jun 17
IVA: Equity Raise And New Financing Will Support Upcoming MASH Milestones
Analysts have adjusted their price target on Inventiva to €15.37 from €11.40, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E, along with recent Street research such as Stifel's revised target. What's in the News for Inventiva Inventiva completed a follow on equity offering of American Depositary Shares, raising about US$120.0 million through the issuance of 27,272,727 ADSs at a price of US$4.40 per security, at a discount of US$0.264 per ADS.
내러티브 업데이트 • Jun 03
IVA: 2026 MASH Phase 3 Milestones Will Drive Bullish Repricing Potential
Analysts have nudged their fair value estimate for Inventiva slightly higher to about €10.09, reflecting updated assumptions on the discount rate and future P/E following a lower price target from Stifel and a fresh bullish initiation from Truist. Analyst Commentary Recent research views on Inventiva point in different directions, with bullish analysts focusing on long term upside potential and bearish analysts placing more weight on execution risks and valuation discipline.내러티브 업데이트 • May 19
IVA: 2026 MASH Phase 3 Readout Will Underpin Bullish Repricing Outlook
Analysts have trimmed their fair value estimate for Inventiva slightly from about €10.00 to about €9.97, pointing to updated assumptions around profit margins and a higher future P/E that balance recent caution from one research house with a more bullish initiation from another. Analyst Commentary Bullish Takeaways Bullish analysts see the slightly higher assumed future P/E as support for the idea that investors may be willing to pay up for the stock if execution on the current pipeline stays on track.내러티브 업데이트 • May 04
IVA: 2026 MASH Phase 3 Readout Will Drive Repricing Thesis
Analysts have trimmed their price target on Inventiva by €2, reflecting slightly more cautious revenue growth assumptions, expectations for stronger profit margins, and a marginally lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see the revised price target as still consistent with meaningful upside potential if Inventiva can deliver on revenue expectations and margin improvement.내러티브 업데이트 • Apr 20
IVA: 2026 MASH Phase 3 Readout Will Support Repricing Thesis
Analysts now see Inventiva’s fair value holding at €10.00, with the latest price target update explained by a slightly higher discount rate, adjusted revenue growth and margin assumptions, and a lower future P/E multiple following recent initiation and target revision reports from several firms. Analyst Commentary Recent Street research on Inventiva points to a mix of optimism around the long term setup and caution around execution risk.내러티브 업데이트 • Apr 06
IVA: 2026 MASH Phase 3 Readout Will Drive Repricing Narrative
The analyst price target for Inventiva has shifted from €8.98 to about €10.00, reflecting updated analyst views that balance a slightly higher discount rate with Street research highlighting lanifibranor's profile in MASH and recent supportive coverage from multiple firms. Analyst Commentary Street research around Inventiva centers on how effectively the company can turn lanifibranor's MASH profile into a de-risked late stage asset and how that potential squares with recent price target resets and rating changes.내러티브 업데이트 • Mar 23
IVA: Bullish MASH Program Coverage Will Highlight Upcoming Clinical Milestone Catalysts
The analyst price target for Inventiva has been revised to €11.40. This reflects analysts' use of a slightly higher discount rate, an updated view on very large revenue growth potential, and adjusted future P/E assumptions informed by recent bullish initiations and upgrades on the stock.내러티브 업데이트 • Mar 08
IVA: 2026 MASH Phase 3 Readout Expected To Drive Bullish Repricing
Analysts have increased their average price target for Inventiva to €12, up from €3, citing fresh bullish initiations and upgrades that highlight lanifibranor's differentiated profile in metabolic dysfunction-associated steatohepatitis, its inclusion among preferred small and mid cap biotech names with key upcoming catalysts, and its broader pipeline. Analyst Commentary Recent research coverage clusters around a constructive view on Inventiva, with several firms setting price targets around €12 and highlighting both the lead MASH asset and the broader pipeline as key pieces of the story.내러티브 업데이트 • Feb 21
IVA: 2026 MASH Phase 3 Readout Will Support Bullish Repricing View
Analysts have raised their Inventiva fair value estimate from €7.85 to approximately €8.98, citing recent Buy and Outperform initiations that underscore confidence in lanifibranor's MASH potential and a modest increase in the assumed future P/E multiple. Analyst Commentary Recent research coverage paints a generally constructive picture for Inventiva, with several firms starting or updating views that focus on lanifibranor's potential in MASH and re-rating the shares using higher P/E assumptions and price targets.내러티브 업데이트 • Feb 07
IVA: Bullish Coverage And Equity Raises Will Highlight Upcoming MASH Catalyst
The analyst price target for Inventiva has moved from $10.00 to $11.40 as analysts factor in recent bullish initiations and upgrades that highlight lanifibranor's profile in MASH and identify the company as part of a group with key upcoming catalysts and broader pipelines. Analyst Commentary Bullish analysts are clustering around a constructive view on Inventiva, pointing to recent initiations and upgrades that anchor higher valuation frameworks to the MASH opportunity and the broader pipeline.내러티브 업데이트 • Jan 22
IVA: 2026 Phase 3 MASH Readout Will Drive Bullish Repricing Narrative
Narrative Update on Inventiva Analysts have raised their price targets on Inventiva to a range of about US$12 to US$13 per share, up from around US$3 in earlier research. They cite new Outperform and Buy ratings that highlight lanifibranor's pan PPAR profile in MASH and upcoming clinical catalysts as key supports for a higher valuation framework.내러티브 업데이트 • Jan 08
IVA: 2026 Phase 3 MASH Readout Expected To Unlock Upside Repricing
Analysts have raised their price target on Inventiva to $12 from $3, citing growing confidence in upcoming lanifibranor data, a broader biotech re-rating, and what they view as a de-risked, best-in-class pipeline with multiple catalysts ahead. Analyst Commentary Recent Street research around Inventiva clusters around a more constructive view of its lead asset lanifibranor and the company’s late stage pipeline, which analysts link directly to their higher valuation frameworks and upgraded views on the stock.내러티브 업데이트 • Dec 23
IVA: 2026 Phase 3 MASH Data Will Drive Upside Repricing
Analysts have modestly reduced their price target on Inventiva to $7.85 from $8.20 while maintaining a constructive stance based on expectations that lanifibranor could show superior fibrosis improvement in the pivotal Phase 3 NATiV3 trial, which is expected in the second half of 2026. Analyst Commentary Bullish analysts highlight that despite the modest reduction in the price target, the longer term valuation framework remains driven by the potential of lanifibranor to outperform currently approved MASH therapies on fibrosis endpoints.내러티브 업데이트 • Dec 09
IVA: 2026 Phase 3 Fibrosis Data Will Drive Significant Upside Potential
Analysts have modestly raised their price target on Inventiva to $13.00, reflecting increased confidence in lanifibranor's potential for superior fibrosis improvement ahead of the pivotal Phase 3 NATiV3 data, which is expected in the second half of 2026. Analyst Commentary Recent Street research highlights a generally constructive stance on Inventiva, anchored by optimism around lanifibranor's potential differentiation in the emerging MASH treatment landscape and the value inflection expected around the Phase 3 NATiV3 readout in the second half of 2026.분석 기사 • Dec 03
These Analysts Think Inventiva S.A.'s (EPA:IVA) Sales Are Under Threat
The latest analyst coverage could presage a bad day for Inventiva S.A. ( EPA:IVA ), with the analysts making...내러티브 업데이트 • Nov 25
IVA: Upcoming 2026 Phase 3 Data Will Unlock Significant Upside Potential
Inventiva's analyst price target has been raised from $7.95 to $8.20 per share. This increase reflects growing optimism among analysts due to increased confidence in lanifibranor's potential Phase 3 efficacy and expanding market opportunities.내러티브 업데이트 • Nov 06
IVA: Phase 3 Readout Will Drive Future Upside Amid Bullish Coverage
Analysts have maintained their fair value estimate for Inventiva at $7.95, citing continued optimism around forthcoming Phase 3 data. There is also a growing consensus on the promising outlook for lanifibranor in the MASH market.분석 기사 • Oct 31
The Price Is Right For Inventiva S.A. (EPA:IVA) Even After Diving 30%
Inventiva S.A. ( EPA:IVA ) shares have retraced a considerable 30% in the last month, reversing a fair amount of their...내러티브 업데이트 • Oct 23
Analysts Boost Inventiva Price Target Amid Optimism for MASH Market and Pipeline Progress
Analysts have raised their average price target for Inventiva from $9 to $13 per share, citing increased optimism for the Metabolic-Associated Steatohepatitis market as well as a larger anticipated target patient population. Analyst Commentary Bullish Takeaways Bullish analysts have increased their price targets, reflecting heightened enthusiasm for the Metabolic-Associated Steatohepatitis market and an anticipated expansion in the eligible patient population.내러티브 업데이트 • Oct 09
Phase III Trials Will Advance Lanifibranor For MASH Treatment
Analysts have increased their fair value estimate for Inventiva from $6.45 to $7.95 per share. They cited greater conviction in revenue growth potential and profit margins for its lead asset in the metabolic disease market.분석 기사 • Oct 08
Revenue Downgrade: Here's What Analysts Forecast For Inventiva S.A. (EPA:IVA)
The latest analyst coverage could presage a bad day for Inventiva S.A. ( EPA:IVA ), with the analysts making...분석 기사 • Sep 04
Need To Know: The Consensus Just Cut Its Inventiva S.A. (EPA:IVA) Estimates For 2025
Today is shaping up negative for Inventiva S.A. ( EPA:IVA ) shareholders, with the analysts delivering a substantial...분석 기사 • Aug 15
There's Reason For Concern Over Inventiva S.A.'s (EPA:IVA) Massive 27% Price Jump
The Inventiva S.A. ( EPA:IVA ) share price has done very well over the last month, posting an excellent gain of 27...
새로운 내러티브 • Apr 02
Phase III Trials Will Advance Lanifibranor For MASH Treatment
Strategic focus on lanifibranor development, cutting other activities, and reducing workforce may improve net margins through operational efficiency.분석 기사 • Apr 02
Need To Know: Analysts Are Much More Bullish On Inventiva S.A. (EPA:IVA)
Inventiva S.A. ( EPA:IVA ) shareholders will have a reason to smile today, with the analysts making substantial...분석 기사 • Feb 27
Revenues Not Telling The Story For Inventiva S.A. (EPA:IVA) After Shares Rise 36%
Inventiva S.A. ( EPA:IVA ) shares have had a really impressive month, gaining 36% after a shaky period beforehand. But...분석 기사 • Sep 27
Inventiva S.A. (EPA:IVA) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
Unfortunately for some shareholders, the Inventiva S.A. ( EPA:IVA ) share price has dived 28% in the last thirty days...분석 기사 • Jun 18
More Unpleasant Surprises Could Be In Store For Inventiva S.A.'s (EPA:IVA) Shares After Tumbling 28%
Inventiva S.A. ( EPA:IVA ) shareholders that were waiting for something to happen have been dealt a blow with a 28...분석 기사 • Jun 14
Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why
Key Insights Inventiva to hold its Annual General Meeting on 20th of June Total pay for CEO Frederic Cren includes...분석 기사 • Mar 19
Optimistic Investors Push Inventiva S.A. (EPA:IVA) Shares Up 27% But Growth Is Lacking
Those holding Inventiva S.A. ( EPA:IVA ) shares would be relieved that the share price has rebounded 27% in the last...분석 기사 • Jan 16
Some Confidence Is Lacking In Inventiva S.A.'s (EPA:IVA) P/S
When close to half the companies in the Biotechs industry in France have price-to-sales ratios (or "P/S") below 5.8x...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 213 | -59 | 80 | 34 | 10 |
| 12/31/2027 | 118 | -91 | 341 | 200 | 11 |
| 12/31/2026 | 5 | -148 | -47 | -74 | 11 |
| 12/31/2025 | 7 | -354 | -105 | -105 | N/A |
| 9/30/2025 | 12 | -333 | -98 | -98 | N/A |
| 6/30/2025 | 17 | -311 | -91 | -91 | N/A |
| 3/31/2025 | 16 | -248 | -89 | -89 | N/A |
| 12/31/2024 | 14 | -184 | -86 | -86 | N/A |
| 9/30/2024 | 17 | -144 | -86 | -85 | N/A |
| 6/30/2024 | 19 | -104 | -85 | -85 | N/A |
| 3/31/2024 | 21 | -107 | -84 | -83 | N/A |
| 12/31/2023 | 23 | -110 | -82 | -82 | N/A |
| 9/30/2023 | 22 | -95 | -73 | -73 | N/A |
| 6/30/2023 | 22 | -80 | -64 | -64 | N/A |
| 3/31/2023 | 20 | -67 | -55 | -54 | N/A |
| 12/31/2022 | 18 | -54 | -45 | -45 | N/A |
| 9/30/2022 | 14 | -55 | -50 | -49 | N/A |
| 6/30/2022 | 10 | -56 | -55 | -54 | N/A |
| 3/31/2022 | 10 | -56 | -54 | -53 | N/A |
| 12/31/2021 | 9 | -50 | -48 | -48 | N/A |
| 9/30/2021 | 7 | -45 | -46 | -45 | N/A |
| 6/30/2021 | 6 | -41 | -44 | -43 | N/A |
| 3/31/2021 | 5 | -36 | -35 | -35 | N/A |
| 12/31/2020 | 5 | -34 | -31 | -31 | N/A |
| 9/30/2020 | 7 | -29 | -24 | -24 | N/A |
| 6/30/2020 | 10 | -25 | -17 | -17 | N/A |
| 3/31/2020 | 10 | -27 | -23 | -23 | N/A |
| 12/31/2019 | 11 | -30 | -29 | -28 | N/A |
| 9/30/2019 | 9 | -34 | N/A | -33 | N/A |
| 6/30/2019 | 7 | -37 | N/A | -38 | N/A |
| 3/31/2019 | 8 | -35 | N/A | -35 | N/A |
| 12/31/2018 | 7 | -33 | N/A | -34 | N/A |
| 9/30/2018 | 8 | -29 | N/A | -27 | N/A |
| 6/30/2018 | 9 | -25 | N/A | -21 | N/A |
| 3/31/2018 | 9 | -22 | N/A | -19 | N/A |
| 12/31/2017 | 10 | -19 | N/A | -17 | N/A |
| 9/30/2017 | 11 | -16 | N/A | -18 | N/A |
| 6/30/2017 | 13 | -13 | N/A | -19 | N/A |
| 3/31/2017 | 14 | -10 | N/A | -17 | N/A |
| 12/31/2016 | 14 | -7 | N/A | -15 | N/A |
| 9/30/2016 | 13 | -8 | N/A | -14 | N/A |
| 6/30/2016 | 12 | -8 | N/A | -13 | N/A |
| 3/31/2016 | 10 | -9 | N/A | -13 | N/A |
| 12/31/2015 | 9 | -9 | N/A | -14 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: IVA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: IVA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: IVA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: IVA 의 수익(연간 51.3%)이 French 시장(연간 5.7%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: IVA 의 수익(연간 51.3%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: IVA의 자본 수익률은 3년 후 33.8%로 높을 것으로 예상됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/24 20:36 |
| 종가 | 2026/06/24 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Inventiva S.A.는 22명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Eliana Merle | Barclays |
| Edward Nash | Canaccord Genuity |
| Etzer Darout | Guggenheim Securities, LLC |